EP1964852A4 - Anticorps anti-ilt7 - Google Patents

Anticorps anti-ilt7

Info

Publication number
EP1964852A4
EP1964852A4 EP06842945A EP06842945A EP1964852A4 EP 1964852 A4 EP1964852 A4 EP 1964852A4 EP 06842945 A EP06842945 A EP 06842945A EP 06842945 A EP06842945 A EP 06842945A EP 1964852 A4 EP1964852 A4 EP 1964852A4
Authority
EP
European Patent Office
Prior art keywords
ilt7 antibodies
ilt7
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06842945A
Other languages
German (de)
English (en)
Other versions
EP1964852B1 (fr
EP1964852A1 (fr
Inventor
Yumiko Kamogawa
Minkwon Cho
Naoko Arai
Koji Ishida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL12168586T priority Critical patent/PL2532681T3/pl
Priority to EP12168586.1A priority patent/EP2532681B1/fr
Priority to DK12168586.1T priority patent/DK2532681T3/en
Priority to SI200631608T priority patent/SI1964852T1/sl
Priority to PL06842945T priority patent/PL1964852T3/pl
Priority to PL14186905T priority patent/PL2913343T3/pl
Priority to EP14186905.7A priority patent/EP2913343B1/fr
Priority to EP18187761.4A priority patent/EP3441403A1/fr
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Publication of EP1964852A1 publication Critical patent/EP1964852A1/fr
Publication of EP1964852A4 publication Critical patent/EP1964852A4/fr
Application granted granted Critical
Publication of EP1964852B1 publication Critical patent/EP1964852B1/fr
Priority to CY20131100538T priority patent/CY1114227T1/el
Priority to CY20181101167T priority patent/CY1121294T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
EP06842945.5A 2005-12-20 2006-12-20 Anticorps anti-ilt7 Active EP1964852B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK12168586.1T DK2532681T3 (en) 2005-12-20 2006-12-20 Anti-ILT7 antibody
SI200631608T SI1964852T1 (sl) 2005-12-20 2006-12-20 Proti-ilt7 protitelo
PL06842945T PL1964852T3 (pl) 2005-12-20 2006-12-20 Przeciwciało anty-ilt7
PL14186905T PL2913343T3 (pl) 2005-12-20 2006-12-20 Przeciwciało przeciw ilt7
EP14186905.7A EP2913343B1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ILT7
EP18187761.4A EP3441403A1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ilt7
PL12168586T PL2532681T3 (pl) 2005-12-20 2006-12-20 Przeciwciało anty-ILT7
EP12168586.1A EP2532681B1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ILT7
CY20131100538T CY1114227T1 (el) 2005-12-20 2013-07-02 Αντισωμα αντι-ilt7
CY20181101167T CY1121294T1 (el) 2005-12-20 2018-11-07 Αντι-ilt7 αντισωμα

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
PCT/JP2006/325391 WO2007072866A1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ilt7

Related Child Applications (5)

Application Number Title Priority Date Filing Date
EP12168586.1A Division EP2532681B1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ILT7
EP14186905.7A Division EP2913343B1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ILT7
EP18187761.4A Division EP3441403A1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ilt7
EP12168582.0 Division-Into 2012-05-18
EP12168586.1 Division-Into 2012-05-18

Publications (3)

Publication Number Publication Date
EP1964852A1 EP1964852A1 (fr) 2008-09-03
EP1964852A4 true EP1964852A4 (fr) 2010-02-24
EP1964852B1 EP1964852B1 (fr) 2013-04-17

Family

ID=38188642

Family Applications (4)

Application Number Title Priority Date Filing Date
EP18187761.4A Withdrawn EP3441403A1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ilt7
EP12168586.1A Active EP2532681B1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ILT7
EP06842945.5A Active EP1964852B1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ilt7
EP14186905.7A Active EP2913343B1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ILT7

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP18187761.4A Withdrawn EP3441403A1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ilt7
EP12168586.1A Active EP2532681B1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ILT7

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14186905.7A Active EP2913343B1 (fr) 2005-12-20 2006-12-20 Anticorps anti-ILT7

Country Status (29)

Country Link
US (6) US8084585B2 (fr)
EP (4) EP3441403A1 (fr)
JP (2) JP5020828B2 (fr)
KR (3) KR101585532B1 (fr)
CN (5) CN101379089B (fr)
AU (1) AU2006328470B2 (fr)
BR (1) BRPI0620141B1 (fr)
CA (2) CA2634116C (fr)
CY (3) CY1114227T1 (fr)
DK (3) DK2532681T3 (fr)
ES (3) ES2416716T3 (fr)
HK (1) HK1218126A1 (fr)
HR (2) HRP20130494T1 (fr)
HU (1) HUE039865T2 (fr)
IL (1) IL192266A (fr)
LT (1) LT2913343T (fr)
ME (1) ME02111B (fr)
MX (1) MX2008007682A (fr)
NZ (3) NZ569910A (fr)
PL (3) PL2532681T3 (fr)
PT (3) PT2532681E (fr)
RS (2) RS53752B1 (fr)
RU (2) RU2456298C2 (fr)
SG (2) SG170749A1 (fr)
SI (3) SI2532681T1 (fr)
TR (1) TR201816574T4 (fr)
UA (1) UA97946C2 (fr)
WO (1) WO2007072866A1 (fr)
ZA (1) ZA200805850B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
WO2011060076A1 (fr) * 2009-11-10 2011-05-19 Amgen Inc. Anticorps anti-c-mpl
WO2011063237A2 (fr) 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Agents de liaison au jagged et utilisations associées
AR080301A1 (es) 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
EP3085387A1 (fr) 2010-04-26 2016-10-26 Abraxis BioScience, LLC Anticorps se liant aux sparc et leurs utilisations
PL2694106T3 (pl) 2011-04-01 2018-06-29 Immunogen, Inc. Sposoby zwiększania skuteczności terapii przeciwnowotworowej opartej na receptorze folr1
DK2828292T3 (da) 2012-03-20 2019-01-02 Biogen Ma Inc Jcv-neutraliserende antistoffer
DK2828284T3 (da) 2012-03-20 2019-06-11 Biogen Ma Inc Jcv-neutraliserende antistoffer
WO2014022758A1 (fr) * 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Anticorps de liaison double à agent unique anti-pd-l1 et pd-l2 et procédés d'utilisation
KR20150046316A (ko) 2012-08-31 2015-04-29 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
PT3038650T (pt) 2013-08-30 2021-08-25 Immunogen Inc Anticorpos e ensaios para a deteção do recetor de folato 1
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN114292331A (zh) * 2013-12-24 2022-04-08 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EA035374B1 (ru) * 2015-03-18 2020-06-03 Сиэтл Дженетикс, Инк. Антитела против cd48 и их конъюгаты
SMT202100092T1 (it) * 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
EP3377079A1 (fr) * 2015-11-19 2018-09-26 Abbvie Stemcentrx LLC Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
EP3407820A4 (fr) 2016-01-26 2019-11-06 Cyberdontics, Inc. Système de traitement dentaire automatisé
WO2017132486A1 (fr) * 2016-01-27 2017-08-03 Siamab Therapeutics, Inc. Compositions et méthodes de ciblage de cellules souches cancéreuses
KR20250065434A (ko) * 2016-03-01 2025-05-12 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
JP6979976B2 (ja) * 2016-03-10 2021-12-15 ヴィエラ バイオ，インコーポレーテッド Ｉｌｔ７結合分子及びその使用方法
WO2017176651A1 (fr) 2016-04-04 2017-10-12 True North Therapeutics, Inc. Anticorps anti-facteur bb du complément et utilisations de ceux-ci
EP3589319A4 (fr) 2017-03-03 2021-07-14 Seagen Inc. Composés interagissant avec le glycane et méthodes d'utilisation
CA3073733A1 (fr) * 2017-08-30 2019-03-07 Phanes Therapeutics, Inc. Anticorps anti-lag-3 et leurs utilisations
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
KR102478433B1 (ko) * 2017-11-17 2022-12-15 머크 샤프 앤드 돔 엘엘씨 이뮤노글로불린-유사 전사체 3 (ilt3)에 대해 특이적인 항체 및 그의 용도
AU2018392717A1 (en) * 2017-12-20 2020-07-09 Albert Einstein College Of Medicine Antibodies to Centrin-1, methods of making, and uses thereof
US11655295B2 (en) * 2018-01-18 2023-05-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-LAG-3 antibody and use thereof
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
MX2020011894A (es) 2018-05-10 2021-03-29 Cyberdontics Usa Inc Taladro dental automatizado.
CN114555637B (zh) * 2019-08-12 2026-01-06 比昂生物制剂公司 针对ilt2的抗体及其用途
EP4041392A1 (fr) 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Anticorps dirigés contre le récepteur du poliovirus (pvr) et leurs utilisations
WO2021113702A1 (fr) * 2019-12-06 2021-06-10 Viela Bio, Inc. Méthodes de traitement à l'aide de protéines de liaison à l'ilt7
PH12022552558A1 (en) 2020-04-20 2024-04-22 Genzyme Corp Humanized anti-complement factor bb antibodies and uses thereof
EP4208122B1 (fr) 2020-09-03 2026-02-11 Perceptive Technologies, Inc. Système pour diriger un foret dentaire automatique
AU2022270101A1 (en) 2021-05-04 2023-10-05 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
JP2025526370A (ja) 2022-07-27 2025-08-13 ビエラ バイオ インコーポレイテッド 免疫グロブリン様転写物７（ｉｌｔ７）結合タンパク質を含む製剤
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
EP4680344A1 (fr) * 2023-03-16 2026-01-21 Inmagene Pte. Ltd. Anticorps ciblant ilt7 et leurs utilisations
WO2024229470A1 (fr) 2023-05-04 2024-11-07 Perceptive Technologies, Inc. Système dentaire robotique et procédé de préparation d'une intervention dentaire robotique
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
WO2025118871A1 (fr) * 2023-12-05 2025-06-12 苏州普乐康医药科技有限公司 Anticorps anti-bdca-2, son procédé de préparation et son utilisation
WO2026002175A1 (fr) * 2024-06-27 2026-01-02 无锡徕特康生物科技有限公司 Anticorps d'activation de cellules myéloïdes ciblant ilt7 et cd89 et son utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP1156823B1 (fr) * 1999-02-12 2008-10-29 The Scripps Research Institute Methodes de traitement des tumeurs et des metastases au moyen d'une combinaison de therapies anti-angiogeniques et d'immunotherapies
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
US20040241167A1 (en) * 2001-06-25 2004-12-02 Nicole Suciu-Foca Ilt3 and ilt4-related compositons and methods
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
PL369953A1 (en) * 2001-10-13 2005-05-02 Asterion Limited Glycosylphosphatidylinositol containing polypeptides
NZ536475A (en) * 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
EP1664762A4 (fr) 2003-09-03 2008-08-13 Us Gov Health & Human Serv Procedes d'identification, de diagnostic et de prediction pour la survie des lymphomes
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. BLASIUS ET AL.: "A cell-surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-alpha.", BLOOD, vol. 103, no. 11, 1 June 2004 (2004-06-01), U.S.A., pages 4201 - 4206, XP002991726 *
A. DZIONEK ET AL.: "BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 194, no. 12, 17 December 2001 (2001-12-17), U.S.A., pages 1823 - 1834, XP002277387 *
C. ASSELIN-PATUREL ET AL.: "Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody.", THE JOURNAL OF IMMUNLOGY, vol. 171, 2003, U.S.A., pages 6466 - 6477, XP002984375 *
See also references of WO2007072866A1 *
X-S. JU ET AL.: "Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation.", GENE, vol. 331, 28 April 2004 (2004-04-28), The Netherlands, pages 159 - 164, XP004503527 *

Also Published As

Publication number Publication date
US20120135003A1 (en) 2012-05-31
CN101379089A (zh) 2009-03-04
CN101379089B (zh) 2013-08-07
RU2456298C2 (ru) 2012-07-20
MX2008007682A (es) 2008-10-23
JP5420688B2 (ja) 2014-02-19
EP2532681A1 (fr) 2012-12-12
IL192266A (en) 2014-09-30
HRP20141226T1 (hr) 2015-02-27
PT1964852E (pt) 2013-07-10
CA2634116C (fr) 2018-03-27
KR20150031485A (ko) 2015-03-24
PL1964852T3 (pl) 2013-09-30
ZA200805850B (en) 2009-04-29
HRP20130494T1 (en) 2013-08-31
LT2913343T (lt) 2018-11-26
EP2913343B1 (fr) 2018-08-08
DK2532681T3 (en) 2015-01-05
US20090280128A1 (en) 2009-11-12
HK1124347A1 (en) 2009-07-10
US8470992B2 (en) 2013-06-25
JPWO2007072866A1 (ja) 2009-06-04
PL2532681T3 (pl) 2015-03-31
US20130259872A1 (en) 2013-10-03
PL2913343T3 (pl) 2019-03-29
PT2532681E (pt) 2014-12-23
US20170204179A1 (en) 2017-07-20
HK1218126A1 (zh) 2017-02-03
HK1214603A1 (en) 2016-07-29
RU2599450C2 (ru) 2016-10-10
ES2416716T3 (es) 2013-08-02
JP2012143232A (ja) 2012-08-02
RU2008129715A (ru) 2010-01-27
CN105111311B (zh) 2019-10-18
SI2532681T1 (sl) 2015-03-31
CN103360492A (zh) 2013-10-23
ES2699428T3 (es) 2019-02-11
RS53752B1 (sr) 2015-06-30
CN120718150A (zh) 2025-09-30
EP1964852B1 (fr) 2013-04-17
AU2006328470A1 (en) 2007-06-28
KR20080090430A (ko) 2008-10-08
SG10201602095PA (en) 2016-05-30
TR201816574T4 (tr) 2018-11-21
US20200339682A1 (en) 2020-10-29
BRPI0620141B1 (pt) 2024-04-30
KR20140053232A (ko) 2014-05-07
JP5020828B2 (ja) 2012-09-05
US8084585B2 (en) 2011-12-27
CN105111311A (zh) 2015-12-02
AU2006328470A2 (en) 2008-10-09
CY1114227T1 (el) 2016-08-31
AU2006328470B2 (en) 2012-08-16
BRPI0620141A2 (pt) 2011-11-01
CN110776566B (zh) 2025-07-15
DK1964852T3 (da) 2013-07-08
ES2526079T3 (es) 2015-01-05
CY1121294T1 (el) 2020-05-29
IL192266A0 (en) 2008-12-29
CA2994756C (fr) 2020-10-27
KR101624587B1 (ko) 2016-05-26
NZ569910A (en) 2012-06-29
SI1964852T1 (sl) 2013-09-30
US20160130343A1 (en) 2016-05-12
EP2913343A1 (fr) 2015-09-02
DK2913343T3 (en) 2018-11-26
KR101585532B1 (ko) 2016-01-14
NZ616992A (en) 2015-07-31
KR101526934B1 (ko) 2015-06-26
SG170749A1 (en) 2011-05-30
CN110776566A (zh) 2020-02-11
PT2913343T (pt) 2018-11-21
RS52860B (sr) 2013-12-31
CA2634116A1 (fr) 2007-06-28
HUE039865T2 (hu) 2019-02-28
UA97946C2 (ru) 2012-04-10
HK1179638A1 (en) 2013-10-04
RU2012112046A (ru) 2013-10-10
ME02111B (me) 2015-10-20
WO2007072866A1 (fr) 2007-06-28
CY1116031T1 (el) 2017-01-25
EP1964852A1 (fr) 2008-09-03
SI2913343T1 (sl) 2019-01-31
NZ599683A (en) 2013-11-29
EP3441403A1 (fr) 2019-02-13
CA2994756A1 (fr) 2007-06-28
EP2532681B1 (fr) 2014-10-01

Similar Documents

Publication Publication Date Title
NO2021050I1 (no) tralokinumab
HRP20150176T1 (xx) Protutijela protiv miostatina
NO20076607L (no) TWEAK - bindende antistoff
DK1964852T3 (da) Anti-ilt7-antistof
EP2076614A4 (fr) Anticorps synthetiques
EP1850873A4 (fr) Anticorps anti-tgf-beta
CY2016030I1 (el) Αντισωματα εναντι της il-17
NO20071430L (no) Anti-OX4OL antistoffer
EP2211903A4 (fr) Anticorps anti-cll-1
EP2102238A4 (fr) Anticorps anti-cd44
EP1877075A4 (fr) Anticorps diriges contre la myostatine
EP2011869A4 (fr) Nouvel anticorps anti-cd98
EP1893084A4 (fr) Detecteur d'analyte
EP1853313A4 (fr) Anticorps humanises l243
EP1765396A4 (fr) Anticorps
ATE408603T1 (de) Pyrazolylcarboxanilide
CR9974A (es) Gavión
EP2172483A4 (fr) ANTICORPS ANTI-Muc17
FI20055649L (fi) Paikanmääritystekniikoita
EP2212431A4 (fr) Anticorps anti-irem-1
DE602006012066D1 (de) Daraus
PL2278284T3 (pl) Zestaw ważący
EP1916896A4 (fr) Antiandrogenes non steroidiens
EP1937814A4 (fr) Anticorps protéiques anti-apoptotiques
DE502006006589D1 (de) Teils

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080710

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ISHIDA, KOJI

Inventor name: ARAI, NAOKO

Inventor name: CHO, MINKWON

Inventor name: KAMOGAWA, YUMIKO

A4 Supplementary search report drawn up and despatched

Effective date: 20100127

17Q First examination report despatched

Effective date: 20100518

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/09 20060101ALI20120416BHEP

Ipc: G01N 33/68 20060101ALI20120416BHEP

Ipc: G01N 33/566 20060101ALI20120416BHEP

Ipc: G01N 33/577 20060101ALI20120416BHEP

Ipc: G01N 33/53 20060101ALI20120416BHEP

Ipc: C12P 21/08 20060101ALI20120416BHEP

Ipc: C12N 5/10 20060101ALI20120416BHEP

Ipc: A61P 43/00 20060101ALI20120416BHEP

Ipc: A61P 37/02 20060101ALI20120416BHEP

Ipc: A61P 35/00 20060101ALI20120416BHEP

Ipc: A61P 31/18 20060101ALI20120416BHEP

Ipc: A61P 17/06 20060101ALI20120416BHEP

Ipc: A61K 48/00 20060101ALI20120416BHEP

Ipc: A61K 39/395 20060101ALI20120416BHEP

Ipc: C07K 16/28 20060101AFI20120416BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 607266

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130515

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20130494

Country of ref document: HR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006035784

Country of ref document: DE

Effective date: 20130613

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MEYER AND KOLLEGEN, CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20130701

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2416716

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20130802

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20130401293

Country of ref document: GR

Effective date: 20130711

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20130494

Country of ref document: HR

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 14501

Country of ref document: SK

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E008291

Country of ref document: EE

Effective date: 20130716

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140120

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006035784

Country of ref document: DE

Effective date: 20140120

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E019183

Country of ref document: HU

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151220

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20170710

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20130494

Country of ref document: HR

Payment date: 20181129

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20190612

Year of fee payment: 13

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20130494

Country of ref document: HR

Payment date: 20191029

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20191212

Year of fee payment: 14

Ref country code: SE

Payment date: 20191210

Year of fee payment: 14

Ref country code: FI

Payment date: 20191209

Year of fee payment: 14

Ref country code: DE

Payment date: 20191210

Year of fee payment: 14

Ref country code: IE

Payment date: 20191209

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20191210

Year of fee payment: 14

Ref country code: DK

Payment date: 20191210

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20191213

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20191219

Year of fee payment: 14

Ref country code: ES

Payment date: 20200102

Year of fee payment: 14

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20130494

Country of ref document: HR

Payment date: 20201218

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20201110

Year of fee payment: 15

Ref country code: CZ

Payment date: 20201126

Year of fee payment: 15

Ref country code: LT

Payment date: 20201123

Year of fee payment: 15

Ref country code: HU

Payment date: 20201122

Year of fee payment: 15

Ref country code: GR

Payment date: 20201112

Year of fee payment: 15

Ref country code: MC

Payment date: 20201127

Year of fee payment: 15

Ref country code: FR

Payment date: 20201112

Year of fee payment: 15

Ref country code: RO

Payment date: 20201201

Year of fee payment: 15

Ref country code: AT

Payment date: 20201125

Year of fee payment: 15

Ref country code: PT

Payment date: 20201220

Year of fee payment: 15

Ref country code: BG

Payment date: 20201020

Year of fee payment: 15

Ref country code: EE

Payment date: 20201123

Year of fee payment: 15

Ref country code: CY

Payment date: 20201113

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20201106

Year of fee payment: 15

Ref country code: SI

Payment date: 20201028

Year of fee payment: 15

Ref country code: SK

Payment date: 20201113

Year of fee payment: 15

Ref country code: LV

Payment date: 20201125

Year of fee payment: 15

Ref country code: BE

Payment date: 20201116

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20201217

Year of fee payment: 15

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006035784

Country of ref document: DE

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201220

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20210101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20201220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201220

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201221

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201220

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210701

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201221

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20130494

Country of ref document: HR

Effective date: 20211220

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E008291

Country of ref document: EE

Effective date: 20211231

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20211220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211220

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220620

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211231

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211220

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211220

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 14501

Country of ref document: SK

Effective date: 20211220

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 607266

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191220

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211220

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20211231

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20220817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211220

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211220

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220706

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211231

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220630

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211221

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211221

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220707